/
EDIT
$3.20+$0.35 (+12.28%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$437.4M
153M shares
52-week range
$1.66 – $4.54
54% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-53.44
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $31.9M | $20.5M | $90.7M | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M |
| Cost of revenue | $90.7M | $96.9M | $158.0M | $5.1M | $6.3M | $6.1M | $199.2M | $0 |
| Gross profit | −$58.7M | −$76.4M | −$67.3M | $20.5M | $13.4M | $72.1M | −$166.9M | $40.5M |
| Gross margin | -183.9% | -372.0% | -74.1% | 80.2% | 67.9% | 92.2% | -516.6% | 100.0% |
| R&D | $90.7M | $96.9M | $158.0M | $142.5M | $175.0M | $177.7M | $199.2M | $90.0M |
| Operating income | −$113.7M | −$140.9M | −$134.8M | −$193.1M | −$225.9M | −$169.2M | −$251.2M | −$99.3M |
| EBITDA | −$110.5M | −$138.1M | −$130.9M | −$187.4M | −$214.1M | −$147.2M | −$233.1M | −$148.6M |
| Net income | −$110.0M | −$133.7M | −$116.0M | −$192.5M | −$220.4M | −$153.2M | −$237.1M | −$160.1M |
| Net margin | -344.3% | -651.4% | -127.8% | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| EPS (diluted) | -2.33 | -2.47 | -1.98 | -2.85 | -3.21 | -2.02 | -2.88 | -1.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $14M | $-0.99 | $-1.19–$-0.58 | 8 |
| 2027 | $15M | $-0.95 | $-1.28–$-0.44 | 7 |
| 2028 | $9M | $-1.04 | $-1.16–$-0.93 | 4 |
| 2029 | $11M | $-1.02 | $-2.06–$-0.41 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Editas Medicine, Inc. Common Stock
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
www.editasmedicine.com- Employees
- 87
- IPO / List date
- Feb 3, 2016
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds EDIT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 3,972,160 | $9.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded EDIT yet.
